Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

06 febbraio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Feb 6, 2023 | 2023, Investors, Press Releases

More details

30 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Jan 30, 2023 | 2023, Investors, Press Releases

More details

23 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Jan 23, 2023 | 2023, Investors, Press Releases

More details

16 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Jan 16, 2023 | 2023, Investors, Press Releases

More details

09 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Jan 9, 2023 | 2023, Investors, Press Releases

More details

02 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Jan 2, 2023 | 2023, Investors, Press Releases

More details
« Older Entries
Next Entries »

Recent Posts

  • 20 marzo 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen to attend the 74th Mosbacher Kolloquium in Mosbach/Baden, on March 23-25, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it